Actelion re-enters transaction talks with Johnson & Johnson
Frankfurt
SWISS biotech company Actelion has turned back to prospective bidder Johnson & Johnson (J&J) for exclusive talks about a "strategic transaction", in an about-turn that appears to sideline rival suitor Sanofi.
Actelion said in a brief statement on Wednesday that it was in exclusive negotiations with the US health care giant but that there could be "no assurance any transaction will result from these discussions", declining to comment further.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO